Trials / Completed
CompletedNCT03949894
Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and therapeutic effectiveness of tolvaptan when administered to slow the progression of cyst development and renal function insufficiency in adult Korean patients diagnosed with rapidly progressive ADPKD who have chronic kidney disease (CKD) stages 1-3 at initiation of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tolvaptan | 30mg and 15mg of Tolvaptan Tablet |
Timeline
- Start date
- 2019-07-01
- Primary completion
- 2022-05-25
- Completion
- 2022-05-25
- First posted
- 2019-05-14
- Last updated
- 2022-06-16
Locations
18 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03949894. Inclusion in this directory is not an endorsement.